BioTuesdays

Category - Markets

Biodesix Logo
Markets

Analysts start Biodesix at buy and OP

Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

November 23, 2020
Silence-Therapeutics-Logo
Markets

BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

November 18, 2020
IMAC-Logo
Markets

AGP starts IMAC Holdings at buy; PT $2.75

Alliance Global Partners launched coverage of IMAC Holdings (NASDAQ:IMAC) with a “buy” rating and price target of $2.75. The stock closed at $1.05 on Nov. 16. IMAC offers regenerative medicine treatments including...

November 17, 2020
Opthea-Logo
Markets

SVB Leerink starts Opthea at OP; PT $33

SVB Leerink launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $33 price target. The stock closed at $13.19 on Nov. 10. “The basis for our recommendation and valuation is our forecast for revenue...

November 11, 2020
Markets

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

November 10, 2020
PDS Biotechnology Logo
Markets

HCW ups PDS Biotechnology to buy; PT $6

H.C. Wainwright upgraded PDS Biotechnology (NASDAQ:PDSB) to “buy” from “neutral” with a price target of $6. The stock closed at $2.04 on Nov. 9. In March 2020, HCW downgraded PDS based on dilution, significantly reduced...

November 10, 2020
Syros-Logo
Markets

Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...

November 10, 2020
Codiak-Logo
Markets

William Blair starts Codiak BioSciences at OP

William Blair launched coverage of Codiak BioSciences (NASDAQ:CDAK) with an “outperform” rating based on the potential of the company’s novel exosome platform and clinical readouts over the next six-to-nine months...

November 9, 2020